2026 · 3rd Quarter (July 1 - Sep 30)

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Filed by AEGIS LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 17, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: AEGIS LLC
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filing UUID: 447e78c7-c4ef-4e16-b3f6-195fe986ced6
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. Global Benchmark for Efficient Drug Pricing (GLOBE) Model.

Literal federal measure citations: H.R.1492, H.R.5378, H.R.5376, H.R.6283, S.1542, H.R.830

HCR · Health Issues

General health care issues. Proposed regulations.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.